Showing 2,601 - 2,620 results of 20,223 for search '(( significantly increased decrease ) OR ( significant ((i decrease) OR (a decrease)) ))', query time: 0.91s Refine Results
  1. 2601

    Fig 6 - by Xinyi Xia (7516694)

    Published 2024
    Subjects:
  2. 2602

    Fig 7 - by Xinyi Xia (7516694)

    Published 2024
    Subjects:
  3. 2603

    Fig 2 - by Xinyi Xia (7516694)

    Published 2024
    Subjects:
  4. 2604

    Fig 8 - by Xinyi Xia (7516694)

    Published 2024
    Subjects:
  5. 2605

    Fig 4 - by Xinyi Xia (7516694)

    Published 2024
    Subjects:
  6. 2606
  7. 2607
  8. 2608
  9. 2609
  10. 2610

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  11. 2611

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  12. 2612

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  13. 2613

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  14. 2614
  15. 2615

    Loss of MALS-1 function suppresses the mitochondrial and axon degeneration phenotypes that are caused by loss of RBM-26 function. by Tamjid A. Chowdhury (14149846)

    Published 2024
    “…For panel B, error bars represent the standard error of the mean (<i>n</i> = 25), and statistical significance was analyzed by one-way ANOVA with a Tukey post hoc test (*<i>p</i> < 0.05 and **<i>p</i> < 0.01). …”
  16. 2616
  17. 2617

    Table 1_IP-10 acts early in CV-A16 infection to induce BBB destruction and promote virus entry into the CNS by increasing TNF-α expression.docx by Yajie Hu (550783)

    Published 2024
    “…We observed that the level of IP-10, as well as the TLR3-TRIF-TRAF3-TBK1-NF-κB and RIG-I/MDA5-MAVS-TRAFS-TBK1-NF-κB pathways, which are the upstream of IP-10, were significantly elevated during the course of CV-A16 infection. …”
  18. 2618
  19. 2619
  20. 2620